-
02 May 2024
-
02 May 2024
Ipsen appoints Keira Driansky as EVP, President of North America
PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the Executiv...
-
02 May 2024
-
02 May 2024
Ipsen appoints Keira Driansky as EVP, President of North America
PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the Executiv...
-
02 May 2024
-
02 May 2024
Ipsen appoints Keira Driansky as EVP, President of North America
PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the Executiv...
-
02 May 2024
-
02 May 2024
Ipsen appoints Keira Driansky as EVP, President of North America
PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the Executiv...
-
15 April 2024
- 3 mins read
-
15 April 2024
- 3 mins read
Mighty bonds: Leaning on others living with FOP
Carli and Erin, cross-country best friends, discuss how they’ve realized the importance of a strong support network of immediate family and friends, along with people who have a shared experience of living with FOP. Their connections have been key to nav...
-
29 February 2024
- 4 mins read
-
29 February 2024
- 4 mins read
Shared decision-making: A true patient-centric approach to care
Monia Vial, Senior Vice President, Franchise Head, Rare Disease Business Unit at Ipsen reflects on a conversation with Courageous Parents Network to educate Ipsen colleagues about shared decision-making and potential positive impacts when we better underst...
-
13 February 2024
-
13 February 2024
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
PARIS, FRANCE, 13 February 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus oxaliplatin, fluorour...
-
12 February 2024
- 4 mins read
-
12 February 2024
- 4 mins read
Advocating for Yourself: L. Marie’s Experience with PBC
L. Marie started her career more than 20 years ago helping others access community health programs and healthcare—a skillset she never imagined would eventually be put to use advocating for her own health after being dismissed by her doctors. ...
-
14 December 2023
- 4 mins read
-
14 December 2023
- 4 mins read
Music and Medicine: Understanding the role of epigenetics in cancer research
Dr. Amauri Soares, VP Head of Early Development & Innovation Oncology at Ipsen usesmusic to explain the importance of understanding the genetics of cancer and how the emerging field ofepigenetics could unlock a new paradigm for precision medicine....
-
07 December 2023
-
07 December 2023
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
PARIS, FRANCE, 07 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational elafibranor. An oral...